Avastin (bevacizumab) / Roche - LARVOL DELTA

Usefulness of molecular characterization in diagnostic orientation: a case report (ECP 2025) - " The patient was initially staged as stage IVA, and first-line treatment with vinorelbine therapy was started...Based on this revised differential diagnosis, therapy with capecitabine plus bevacizumab was initiated in July 2024, as recommended for patients with unresectable meta-static colorectal cancer. In some pathological contexts, such as the one just described, formulating a correct diagnosis can be challenging. In these cases, molecular characterization should also be used to prevent inappropriate assessments and ensure correct patient management."

Case report • Clinical • Colorectal Adenocarcinoma • Colorectal Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Rectal Adenocarcinoma • Solid Tumor • KRAS

BNT314-02: A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - P1/2 | N=482 | Recruiting | Sponsor: BioNTech SE | Not yet recruiting ➔ Recruiting

Enrollment open • Colorectal Cancer • Oncology • Solid Tumor

Nivolumab, ipilimumab and bevacizumab together with 2 cycles of induction chemotherapy in patients with non-squamous NSCLC and untreated brain metastases (CA209-7WF / Break B5-BM-NSCLC / AIO-TRK-0220/ass) (ESMO 2025) - No abstract available

Clinical • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Management of Neurofibromatosis Type 2 (PubMed, No Shinkei Geka) - "In patients with preserved cochlear nerve integrity, cochlear implantation is effective, and treatment strategies should be planned with this option in mind. Clinical trials of bevacizumab for pharmacological treatment are currently ongoing in Japan, and the clinical application of anti-vascular endothelial growth factor receptor vaccine therapy is anticipated."

Journal • Review • Brain Cancer • Genetic Disorders • Neurofibromatosis • Oncology • Otorhinolaryngology • Solid Tumor • NF2

reICB: Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade (clinicaltrials.gov) - P2 | N=90 | Recruiting | Sponsor: EuroCityClinic LLC

Checkpoint inhibition • New P2 trial • Cutaneous Melanoma • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor

BELLA: A Phase 2 Study of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer (ESMO 2025) - No abstract available

Clinical • P2 data • Platinum resistant • Oncology • Ovarian Cancer • Solid Tumor

Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases (clinicaltrials.gov) - P1 | N=7 | Recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

New P1 trial • Oncology

INCB 123667-101: Study of INCB123667 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=604 | Recruiting | Sponsor: Incyte Corporation | Trial completion date: Jul 2026 ➔ Aug 2027 | Trial primary completion date: Aug 2025 ➔ Jul 2027

Monotherapy • Trial completion date • Trial primary completion date • Breast Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

ICON8B: GCIG Phase III Randomised Trial Comparing First-line Weekly Dose-Dense Chemotherapy + Bevacizumab To Three-Weekly Chemotherapy + Bevacizumab In High-Risk Stage III-IV Epithelial Ovarian Cancer (EOC): Final Overall Survival (OS) Analysis (ESMO 2025) - No abstract available

Clinical • P3 data • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor

Longitudinal ctDNA Profiling in HER2-Altered NSCLC Treated With HER2 Adc: Preliminary Results From the RESOLUTION Trial (IASLC-WCLC 2025) - "A total of 28 eligible patients will receive disitamab vedotin (2.0 mg/kg), tislelizumab (200 mg), and bevacizumab (7.5 mg/kg), all administered intravenously every 3 weeks, until disease progression or unacceptable toxicity. The first-stage interim analysis revealed acceptable efficacy to support proceeding to the further stage. Longitudinal ctDNA analysis enabled dynamic monitoring of tumor burden and early detection of disease progression, underscoring its potential as a non-invasive tool for real-time treatment response assessment."

Circulating tumor DNA • IO biomarker • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • HER-2 • TP53

circFOXK2 inhibits vascular permeability and angiogenesis in advanced lung adenocarcinoma via the miR-1275/CLDN1 axis. (PubMed, Biochem Biophys Res Commun) - "Notably, combining circFOXK2 overexpression with bevacizumab produced a synergistic effect, suggesting a potential therapeutic strategy. Our findings emphasize the critical role of the circFOXK2/miR-1275/CLDN1 axis in regulating vascular permeability and angiogenesis in advanced LUAD, positioning this axis as a promising therapeutic target."

Journal • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CLDN1 • MIR127

A Novel Finding of Retinal Neovascularization Secondary to Chronic Central Serous Chorioretinopathy. (PubMed, Cureus) - "Comprehensive investigations, including fundus fluorescein angiography, were performed to exclude alternative causes such as diabetic retinopathy, vascular occlusion, or retinal vasculitis. He was treated with three intravitreal injections of bevacizumab and received sectoral panretinal photocoagulation laser with good response and regression of the vessel appearance."

Journal • Age-related Macular Degeneration • Diabetic Retinopathy • Ocular Inflammation • Retinal Disorders • Vasculitis

Precision Oncology Through Dialogue: AI-HOPE-RTK-RAS Integrates Clinical and Genomic Insights into RTK-RAS Alterations in Colorectal Cancer. (PubMed, Biomedicines) - "In KRAS-mutant patients receiving Bevacizumab, early-stage disease (Stages I-III) was associated with superior overall survival relative to Stage IV (p = 0.0004)...Its ability to uncover both canonical and ancestry-specific patterns in RTK-RAS dysregulation-especially in EOCRC and populations with disproportionate health burdens-underscores its utility in advancing equitable, personalized cancer care. This work demonstrates the translational potential of domain-optimized AI tools to accelerate biomarker discovery, support therapeutic stratification, and democratize access to multi-omic analysis."

Journal • Colorectal Cancer • Oncology • Solid Tumor • BRAF • EGFR • KRAS • MAPK3 • NF1 • NRAS

The Hidden Tumor: Pancreatic Cancer Missed by Imaging, Found by Endoscopic Ultrasound (ACG 2025) - "He was treated with FOLFOX-6/Avastin for one year without resolution. EUS examination, as part of his workup for jaundice, confirmed the presence of a pancreatic neuroendocrine tumor. These cases demonstrate the importance of utilizing endoscopic ultrasound in detecting pancreatic neoplasms in the setting of changes in the pancreatic or biliary ducts with incidental radiographic findings. A high level of suspicion is needed when such changes are observed on imaging to assess malignancy, and this would typically be evaluated and biopsied using endoscopic ultrasound.2-4 Given that a considerable number of patients may derive benefit from early diagnosis, further research is warranted to determine optimal screening protocols using EUS."

Colon Cancer • Colorectal Cancer • Hepatology • Immunology • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Pancreatitis • Sjogren's Syndrome • Solid Tumor • CA 19-9 • CEACAM5

A Rare Case of Hepatocellular Carcinoma Presenting With Right Atrial Involvement: Clinical Challenges and Multimodal Treatment (ACG 2025) - "The patient underwent partial surgical resection of the mass, followed by adjuvant immunotherapy with atezolizumab and bevacizumab. Upon disease progression, he received targeted radiotherapy and was subsequently started on oral lenvatinib...The images show large lobulated mass occupying the right atrium (Asterisk) attached to the interatrial septum (Arrows) with inferiorly extending component to the suprahepatic IVC (Dashed Red). The largest dimension of the lesion (craniocaudal) was approximately 6.8 cm."

Clinical • Fibrosis • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Oncology • Solid Tumor

Molecular Pathogenesis, Genetic Profiles, and Therapeutic Strategies for NF2-Related Schwannomatosis (PubMed, No Shinkei Geka) - "Targeted therapies-including bevacizumab, brigatinib, and vascular endothelial growth factor -A vaccines-have shown promise, particularly in refractory cases. Although routine intensive surveillance is not universally required, early genetic screening and long-term follow-ups may benefit select individuals. The comprehensive integration of genetic, pathological, and immunological data is essential for advancing personalized treatment strategies for NF2-SWN."

Journal • Review • Brain Cancer • CNS Tumor • Genetic Disorders • Meningioma • Neurofibromatosis • Oncology • Solid Tumor • NF2

A Phase II, Open-label, Non-comparative, Randomized Study of Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer (clinicaltrials.gov) - P2 | N=74 | Not yet recruiting | Sponsor: Federation Francophone de Cancerologie Digestive

New P2 trial • Colorectal Cancer • Oncology • Solid Tumor • BRAF

Combination of anti-epidermal growth factor receptor antibodies plus trifluridine-tipiracil as rechallenge strategy improves treatment outcomes in patients with RAS/BRAF wild-type refractory metastatic colorectal cancer. (PubMed, Am J Cancer Res) - "Trifluridine/tipiracil (FTD-TPI) plus bevacizumab is an established option for refractory metastatic colorectal cancer (mCRC). After adjustment for age, sex, tumour sidedness and time from metastatic diagnosis to FTD-TPI, anti-EGFR therapy remained the only independent predictor of response (posterior OR ≈ 7; 95% credible interval 1.1-66). These data suggest that FTD-TPI plus anti-EGFR rechallenge provides greater tumour shrinkage and at least comparable survival versus FTD-TPI plus anti-VEGF in heavily pre-treated, wild-type mCRC, supporting further prospective evaluation."

Journal • Colorectal Cancer • Oncology • Solid Tumor • BRAF • EGFR • RAS

Toripalimab Plus Bevacizumab and Chemoradiotherapy as Treatment in Patients With Advanced Melanoma: The IRAC Phase 2 Nonrandomized Clinical Trial (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Melanoma • Oncology • Solid Tumor

The benefits and pitfalls of adding bevacizumab to neoadjuvant chemotherapy for advanced ovarian cancer: a meta-analysis. (PubMed, Future Oncol) - "However, bevacizumab-NACT increased the risk of gastrointestinal perforation. www.crd.york.ac.uk/prospero identifier is CRD42024566484."

Clinical • Journal • Retrospective data • Review • Gastrointestinal Disorder • Infectious Disease • Oncology • Ovarian Cancer • Solid Tumor

Sex and Histology Related Profile of Gut Microbiota (GM) in Pleural Mesothelioma (PM): Preliminary Results of a Prospective Observational Study (IASLC-WCLC 2025) - "A single prospective experience highlights the positive prognostic value of Prevotella and Eubacterium ventriosum and the negative prognostic value of Erysipelatoclostridium in a small cohort of patients treated with atezolizumab and bevacizumab as salvage therapy...Pts were mostly male (41/50), median age was 72 years (IQR 65-76), were treated with pemetrexed and platinum derivatives chemotherapy (34/50), had an epithelioid histology (34/50)...Conclusions : These preliminary results highlight a significant difference in beta diversity as well as species specific GM composition in PM patients, related to histology and sex. Further correlative analyses on the impact of GM composition, its modification during treatment and its association with response and survival are planned."

Clinical • Gut Microbiota • Observational data • Malignant Pleural Mesothelioma • Mesothelioma • Oncology • Pleural Mesothelioma • Solid Tumor

LEAF-02: Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab (clinicaltrials.gov) - P2 | N=141 | Recruiting | Sponsor: Fudan University | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatocellular Cancer • Oncology • Solid Tumor

Efficacy and Safety of Afatinib Plus Bevacizumab as First-Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial. (PubMed, Thorac Cancer) - "Afatinib combined with bevacizumab is well tolerated with moderate efficacy among patients with NSCLC, which might be a prospective strategy for patients with uncommon EGFR mutations and pleural metastasis."

Journal • P2 data • Retrospective data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • EGFR

FTM-JSNO-03:A phase II study of fecal microbiota transplantation (FMT) plus QL1706 plus Bevacizumab plus XELOX for first-line (1L) treatment of advanced Microsatellite-stable (MSS) type colon cancer with liver metastasis (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor

Radiomics-based prediction of HCC response to atezolizumab/bevacizumab. (PubMed, Oncol Lett) - "Advanced hepatocellular carcinoma (HCC) treatment has evolved with the introduction of atezolizumab/bevacizumab, showing improved outcomes over sorafenib. Hyperparameter tuning further enhanced the accuracy of the combined model to 80.1% and the ROC AUC to 0.771 for the test set. In conclusion, the hybrid model combining clinical and radiological data outperformed individual models, providing improved predictions of response to atezolizumab/bevacizumab in patients with HCC."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor